1
|
Fu F, Li X, Chen Y, Li L, Dou J, Liang K, Chen Y, Lu Y, Huang Y. Genotoxicity and cytotoxicity evaluation of a heat-not-burn product. MUTATION RESEARCH. GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS 2024; 897:503784. [PMID: 39054007 DOI: 10.1016/j.mrgentox.2024.503784] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/22/2024] [Revised: 05/26/2024] [Accepted: 05/27/2024] [Indexed: 07/27/2024]
Abstract
'Heat-not-burn' products (HnBP) contain lower levels of harmful substances than traditional cigarettes, but the use of these products warrants further toxicological evaluation. We have compared the cytotoxicity and genotoxicity of a heat-not burn product with conventional cigarettes, in vivo and in vitro. Male Sprague Dawley rats were exposed to mainstream smoke from conventional cigarettes or a HnBP, for 4 or 28 days, followed by isolation of bone marrow polychromatic erythrocytes (PCE) and histological examination of the testes. Chinese hamster lung fibroblast cells were exposed in vitro to total particulate matter from cigarette smoke obtained through Cambridge filters. The cytotoxicity and genotoxicity of total particulate matter were assessed by the neutral red uptake assay, chromosome aberration assay, in vitro micronucleus test, comet assay, and Ames assay. In the short-term exposure rat models, only the conventional-cigarettes group showed a significant increase in the ratio of micronuclei to total PCE. There was no significant difference in rat testis histology in the long-term exposure models. In vitro, in the neutral red uptake assay, the HnBP product showed lower cytotoxicity than conventional cigarettes. Conventional cigarettes showed greater genotoxicity in the chromosome aberration assay, high-dose Ames tests with exogenous metabolic activation, and micronucleus tests. In summary, our results suggest that HnBP have lower cytotoxicity and genotoxicity than conventional cigarettes.
Collapse
Affiliation(s)
- Fudong Fu
- Department of Pulmonary and Critical Care Medicine, and Institutes for Systems Genetics, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China
| | - Xiaoyu Li
- Department of Pulmonary and Critical Care Medicine, and Institutes for Systems Genetics, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China
| | - Younan Chen
- Department of Pulmonary and Critical Care Medicine, and Institutes for Systems Genetics, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China; Key Laboratory of Transplant Engineering and Immunology, NHFPC, Regenerative Medicine Research Center, West China Hospital, Sichuan University, Chengdu, China
| | - Lan Li
- Key Laboratory of Transplant Engineering and Immunology, NHFPC, Regenerative Medicine Research Center, West China Hospital, Sichuan University, Chengdu, China
| | - Jiexiong Dou
- Sichuan Center for Disease Control and Prevention, Chengdu 610044, China
| | - Kun Liang
- Harmful Components and Tar Reduction in Cigarette Key Laboratory of Sichuan Province, Chengdu 610101, China; New Tobacco Products Engineering and Technology Research Center of Sichuan Province, Chengdu 610101 China
| | - Yexian Chen
- Harmful Components and Tar Reduction in Cigarette Key Laboratory of Sichuan Province, Chengdu 610101, China; New Tobacco Products Engineering and Technology Research Center of Sichuan Province, Chengdu 610101 China
| | - Yanrong Lu
- Key Laboratory of Transplant Engineering and Immunology, NHFPC, Regenerative Medicine Research Center, West China Hospital, Sichuan University, Chengdu, China
| | - Yuchuan Huang
- Harmful Components and Tar Reduction in Cigarette Key Laboratory of Sichuan Province, Chengdu 610101, China; New Tobacco Products Engineering and Technology Research Center of Sichuan Province, Chengdu 610101 China.
| |
Collapse
|
2
|
Picanço JMA, Limberger RP, Apel MA. Where should I start? A scoping review about the publications on clove cigarettes. Crit Rev Toxicol 2022; 52:259-293. [PMID: 35971813 DOI: 10.1080/10408444.2022.2097053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
INTRODUCTION The general lack of knowledge about the composition of clove cigarettes and the large number of terms that can be used to define different types of cigarettes that contain cloves makes it difficult to find scientific articles focused on the subject. We reviewed the publications that cited clove cigarettes to assess their relevance. METHODS We searched publications on Scopus, ScienceDirect, PubMed, and Portal CAPES during the first semester of 2021, without date restrictions. Through a quality assessment, the studies found were assorted in ten different categories. RESULTS Indonesian clove cigarettes-also known as kretek-are a mixture of tobacco and cloves rolled in a cigarette and sprayed with oils, plant extract, and food flavorings, in an unknown quantity and composition, different from each brand, which is usually kept in secret. Due to the relatively low prevalence of use in the general population, most publications on tobacco products tend to ignore clove cigarettes or place them in an existing category. Clove cigarettes can be hand-rolled, machine-made, filtered, unfiltered, and each form can be named differently. The interchangeable use of each term, sometimes grouping conventional cigarettes in the mix, can lead the researcher to consider a publication that should be excluded. CONCLUSION The existing regulations on flavored cigarettes, although well-intentioned, are still somewhat vague and broad, leaving possible loopholes that can be exploited by the tobacco industries. Fully understanding the precise effects caused by clove cigarettes can be an important tool in future discussions about tobacco control.
Collapse
Affiliation(s)
| | | | - Miriam Anders Apel
- Faculty of Pharmacy, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
| |
Collapse
|
3
|
Platel A, Dusautoir R, Kervoaze G, Dourdin G, Gateau E, Talahari S, Huot L, Simar S, Ollivier A, Laine W, Kluza J, Gosset P, Garçon G, Anthérieu S, Guidice JML, Nesslany F. Comparison of the in vivo genotoxicity of electronic and conventional cigarettes aerosols after subacute, subchronic and chronic exposures. JOURNAL OF HAZARDOUS MATERIALS 2022; 423:127246. [PMID: 34844363 DOI: 10.1016/j.jhazmat.2021.127246] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/09/2021] [Revised: 09/01/2021] [Accepted: 09/13/2021] [Indexed: 06/13/2023]
Abstract
Tobacco smoking is classified as a human carcinogen. A wide variety of new products, in particular electronic cigarettes (e-cigs), have recently appeared on the market as an alternative to smoking. Although the in vitro toxicity of e-cigs is relatively well known, there is currently a lack of data on their long-term health effects. In this context, the aim of our study was to compare, on a mouse model and using a nose-only exposure system, the in vivo genotoxic and mutagenic potential of e-cig aerosols tested at two power settings (18 W and 30 W) and conventional cigarette (3R4F) smoke. The standard comet assay, micronucleus test and Pig-a gene mutation assay were performed after subacute (4 days), subchronic (3 months) and chronic (6 months) exposure. The generation of oxidative stress was also assessed by measuring the 8-hydroxy-2'-deoxyguanosine and by using the hOGG1-modified comet assay. Our results show that only the high-power e-cig and the 3R4F cigarette induced oxidative DNA damage in the lung and the liver of exposed mice. In return, no significant increase in chromosomal aberrations or gene mutations were noted whatever the type of product. This study demonstrates that e-cigs, at high-power setting, should be considered, contrary to popular belief, as hazardous products in terms of genotoxicity in mouse model.
Collapse
Affiliation(s)
- Anne Platel
- CHU Lille, Institut Pasteur de Lille, ULR 4483-IMPact de l'Environnement Chimique sur la Santé (IMPECS), Univ. Lille, Lille, France.
| | - Romain Dusautoir
- CHU Lille, Institut Pasteur de Lille, ULR 4483-IMPact de l'Environnement Chimique sur la Santé (IMPECS), Univ. Lille, Lille, France.
| | - Gwenola Kervoaze
- University of Lille, CNRS UMR9017, Inserm U1019, CHRU Lille, Institut Pasteur de Lille, CIIL - Center for Infection and Immunity of Lille, OpInfIELD, France.
| | - Gonzague Dourdin
- CHU Lille, Institut Pasteur de Lille, ULR 4483-IMPact de l'Environnement Chimique sur la Santé (IMPECS), Univ. Lille, Lille, France.
| | - Eulalie Gateau
- CHU Lille, Institut Pasteur de Lille, ULR 4483-IMPact de l'Environnement Chimique sur la Santé (IMPECS), Univ. Lille, Lille, France.
| | - Smaïl Talahari
- CHU Lille, Institut Pasteur de Lille, ULR 4483-IMPact de l'Environnement Chimique sur la Santé (IMPECS), Univ. Lille, Lille, France.
| | - Ludovic Huot
- CHU Lille, Institut Pasteur de Lille, ULR 4483-IMPact de l'Environnement Chimique sur la Santé (IMPECS), Univ. Lille, Lille, France.
| | - Sophie Simar
- CHU Lille, Institut Pasteur de Lille, ULR 4483-IMPact de l'Environnement Chimique sur la Santé (IMPECS), Univ. Lille, Lille, France.
| | - Anaïs Ollivier
- University of Lille, CNRS UMR9017, Inserm U1019, CHRU Lille, Institut Pasteur de Lille, CIIL - Center for Infection and Immunity of Lille, OpInfIELD, France.
| | - William Laine
- UMR 9020-UMR-S 1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, Institut de Recherche contre le Cancer de Lille, University Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France.
| | - Jérôme Kluza
- UMR 9020-UMR-S 1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, Institut de Recherche contre le Cancer de Lille, University Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France.
| | - Philippe Gosset
- University of Lille, CNRS UMR9017, Inserm U1019, CHRU Lille, Institut Pasteur de Lille, CIIL - Center for Infection and Immunity of Lille, OpInfIELD, France.
| | - Guillaume Garçon
- CHU Lille, Institut Pasteur de Lille, ULR 4483-IMPact de l'Environnement Chimique sur la Santé (IMPECS), Univ. Lille, Lille, France.
| | - Sébastien Anthérieu
- CHU Lille, Institut Pasteur de Lille, ULR 4483-IMPact de l'Environnement Chimique sur la Santé (IMPECS), Univ. Lille, Lille, France.
| | - Jean-Marc Lo Guidice
- CHU Lille, Institut Pasteur de Lille, ULR 4483-IMPact de l'Environnement Chimique sur la Santé (IMPECS), Univ. Lille, Lille, France.
| | - Fabrice Nesslany
- CHU Lille, Institut Pasteur de Lille, ULR 4483-IMPact de l'Environnement Chimique sur la Santé (IMPECS), Univ. Lille, Lille, France.
| |
Collapse
|
4
|
Stabbert R, Ghosh D, Clarke A, Miller J, Collard J, Crooks I, Tafin Djoko D, Larroque S, Jaccard G, Roemer E, Park CH, Esposito M. Assessment of priority tobacco additives per the requirements in the EU Tobacco Products Directive (2014/40/EU): Part 2: Smoke chemistry and in vitro toxicology. Regul Toxicol Pharmacol 2019; 104:163-199. [DOI: 10.1016/j.yrtph.2019.03.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2018] [Revised: 02/15/2019] [Accepted: 03/01/2019] [Indexed: 01/05/2023]
|
5
|
Simms L, Clarke A, Paschke T, Manson A, Murphy J, Stabbert R, Esposito M, Ghosh D, Roemer E, Martinez J, Freiesleben J, Kim HK, Lindegaard T, Scharfe M, Vincze I, Vlachos P, Wigotzki D, Pollner G, Lutz R. Assessment of priority tobacco additives per the requirements of the EU Tobacco Products Directive (2014/40/EU): Part 1: Background, approach, and summary of findings. Regul Toxicol Pharmacol 2019; 104:84-97. [PMID: 30797887 DOI: 10.1016/j.yrtph.2019.02.011] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2018] [Revised: 02/14/2019] [Accepted: 02/16/2019] [Indexed: 10/27/2022]
Abstract
This paper is part of a series of 3 publications and describes the non-clinical and clinical assessment performed to fulfill the regulatory requirement per Art. 6 (2) of the EU Tobacco Products Directive 2014/40/EU; under which Member States shall require manufacturers and importers of cigarettes and roll-your-own tobacco containing an additive that is included in the priority list established by Commission Implementing Decision (EU) 2016/787 to carry out comprehensive studies. The Directive requires manufacturers and importers of cigarettes and Roll Your Own tobacco to examine for each additive whether it; contributes to and increases the toxicity or addictiveness of tobacco products to a significant or measurable degree; if it leads to a characterizing flavor of the product; if it facilitates inhalation or nicotine uptake, and if it results in the formation of CMR (carcinogenic, mutagenic and reprotoxic) constituents and if these substances increase the CMR properties of the respective tobacco product to a significant or measurable degree. This publication gives an overview on comprehensive smoke chemistry, in vitro toxicity, and human clinical studies commissioned by the members of the Priority Additives Tobacco Consortium to independent Contract Research Organizations (CROs) where the emissions of test cigarettes containing priority additives were compared to emissions emerging from an additive-free reference cigarette. Whilst minor changes in smoke chemistry parameters were observed when comparing emissions from test cigarettes with emissions from additive-free reference cigarettes, only two of the additives (sorbitol and guar gum) tested led to significant increases in a limited number of smoke constituents. These changes were not observed when sorbitol or guar gum were tested in a mixture with other priority additives. None of the priority additives resulted in increases in in vitro toxicity (Ames, Micronucleus, Neutral Red Uptake) or led to changes in smoking behavior or absorption (rate or amount) of nicotine measured during the human clinical study as compared to the additive-free reference cigarette.
Collapse
Affiliation(s)
- Liam Simms
- Imperial Tobacco, 121 Winterstoke Road, Bristol, BS3 2LL, United Kingdom.
| | - Anna Clarke
- Imperial Tobacco, 121 Winterstoke Road, Bristol, BS3 2LL, United Kingdom
| | - Thilo Paschke
- Japan Tobacco International SA, Rue Kazem Radjavi 8, 1202, Geneva, Switzerland
| | - Andrew Manson
- British American Tobacco, Globe House, Temple Place, London, United Kingdom
| | - James Murphy
- British American Tobacco, Research & Development, Regents Park Road, Southampton, SO158TL, United Kingdom
| | - Regina Stabbert
- Philip Morris International, Philip Morris Products SA, Rue des Usines 90, 2000, Neuchâtel, Switzerland
| | - Marco Esposito
- Philip Morris International, Philip Morris Products SA, Rue des Usines 90, 2000, Neuchâtel, Switzerland
| | - David Ghosh
- Philip Morris International, Philip Morris International Management SA, Avenue de Rhodanie 50, 1001, Lausanne, Switzerland
| | - Ewald Roemer
- TobToxConsulting, Imp. Blanchet-Dailleres 9, 1585, Cotterd, Switzerland
| | - Javier Martinez
- Japan Tobacco International SA, Rue Kazem Radjavi 8, 1202, Geneva, Switzerland
| | - Jarl Freiesleben
- Mac Baren Tobacco Company A/S, Porthusvej 100, DK-5700 Svenborg, Denmark
| | - Hyo-Keun Kim
- KT&G Research Institute, 30 Gajeong-ro, Yusong-gu, Daejeon, 34128, Republic of Korea
| | | | - Marc Scharfe
- LandewykTobacco S. A, 31 rue de Hollerich, 1741, Luxembourg B.P, 2202L-1022, Luxembourg
| | - Istvan Vincze
- Continental Tobacco Corporation, Continental Dohányipari Zrt, 1-3, Dohány utca Sátoraljaújhely, 3980, Hungary
| | | | - Diane Wigotzki
- Joh. Wilh. von Eicken GmbH, Drechslerstr. 1 - 3, 23556, Lübeck, Germany
| | - Gwen Pollner
- Pöschl Tabak GmbH & Co. KG, Dieselstrasse 1, 84144, Geisenhausen, Germany
| | - Rolf Lutz
- Philip Morris International, Philip Morris International Management SA, Avenue de Rhodanie 50, 1001, Lausanne, Switzerland
| |
Collapse
|
6
|
Jaccard G, Belushkin M, Jeannet C, Aldilla EN, Ongko Wijoyo A. Investigation of menthol content and transfer rates in cigarettes and Tobacco Heating System 2.2. Regul Toxicol Pharmacol 2019; 101:48-52. [PMID: 30445138 DOI: 10.1016/j.yrtph.2018.11.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2018] [Revised: 10/11/2018] [Accepted: 11/12/2018] [Indexed: 01/27/2023]
Abstract
Menthol cigarettes account for a significant market share in many countries. However, little recent data exists on menthol levels in cigarettes and in mainstream smoke, limited to some markets or specific cigarette designs, such as cigarettes containing capsules filled with flavoring liquids. Samples of mentholated cigarettes bought worldwide with a variety of cigarette designs were analyzed for menthol content in cigarettes and in cigarette mainstream smoke with two analytical machine smoking regimes. A wide range of menthol content in cigarettes, from 1 to 22 mg/cigarette, was observed. The transfer of menthol to the cigarette mainstream smoke was generally slightly higher than the transfer of nicotine, with a range of 17%-40% using an intense smoking regime and 1%-17% using the ISO smoking regime. For the Tobacco Heating System (THS) 2.2, the menthol content was 12.8 mg/stick, and the transfer of menthol into the aerosol was about 17% with the ISO intense smoking regime, similar to the transfer of nicotine. The menthol content of the novel product THS 2.2 corresponds to the midpoint of the menthol content range of cigarettes, and the transfer of menthol to its aerosol is in the low range of cigarette menthol transfer.
Collapse
Affiliation(s)
- Guy Jaccard
- PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, CH-2000, Neuchâtel, Switzerland.
| | - Maxim Belushkin
- PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, CH-2000, Neuchâtel, Switzerland
| | - Cyril Jeannet
- PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, CH-2000, Neuchâtel, Switzerland
| | - Evi Nurlaili Aldilla
- PT HM Sampoerna Tbk. Scientific Technical Services Laboratories, Jl. Raya Surabaya Malang Km 51.4, 67161, Pasuruan, Indonesia
| | - Andry Ongko Wijoyo
- PT HM Sampoerna Tbk. Scientific Technical Services Laboratories, Jl. Raya Surabaya Malang Km 51.4, 67161, Pasuruan, Indonesia
| |
Collapse
|
7
|
Oviedo A, Lebrun S, Kogel U, Ho J, Tan WT, Titz B, Leroy P, Vuillaume G, Bera M, Martin F, Rodrigo G, Esposito M, Dempsey R, Ivanov NV, Hoeng J, Peitsch MC, Vanscheeuwijck P. Evaluation of the Tobacco Heating System 2.2. Part 6: 90-day OECD 413 rat inhalation study with systems toxicology endpoints demonstrates reduced exposure effects of a mentholated version compared with mentholated and non-mentholated cigarette smoke. Regul Toxicol Pharmacol 2016; 81 Suppl 2:S93-S122. [DOI: 10.1016/j.yrtph.2016.11.004] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2016] [Revised: 10/28/2016] [Accepted: 11/01/2016] [Indexed: 10/20/2022]
|
8
|
Dalrymple A, Ordoñez P, Thorne D, Walker D, Camacho OM, Büttner A, Dillon D, Meredith C. Cigarette smoke induced genotoxicity and respiratory tract pathology: evidence to support reduced exposure time and animal numbers in tobacco product testing. Inhal Toxicol 2016; 28:324-38. [PMID: 27160659 PMCID: PMC4898166 DOI: 10.3109/08958378.2016.1170911] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2015] [Revised: 03/03/2016] [Accepted: 03/21/2016] [Indexed: 11/13/2022]
Abstract
Many laboratories are working to develop in vitro models that will replace in vivo tests, but occasionally there remains a regulatory expectation of some in vivo testing. Historically, cigarettes have been tested in vivo for 90 days. Recently, methods to reduce and refine animal use have been explored. This study investigated the potential of reducing animal cigarette smoke (CS) exposure to 3 or 6 weeks, and the feasibility of separate lung lobes for histopathology or the Comet assay. Rats were exposed to sham air or CS (1 or 2 h) for 3 or 6 weeks. Respiratory tissues were processed for histopathological evaluation, and Alveolar type II cells (AEC II) isolated for the Comet assay. Blood was collected for Pig-a and micronucleus quantification. Histopathological analyses demonstrated exposure effects, which were generally dependent on CS dose (1 or 2 h, 5 days/week). Comet analysis identified that DNA damage increased in AEC II following 3 or 6 weeks CS exposure, and the level at 6 weeks was higher than 3 weeks. Pig-a mutation or micronucleus levels were not increased. In conclusion, this study showed that 3 weeks of CS exposure was sufficient to observe respiratory tract pathology and DNA damage in isolated AEC II. Differences between the 3 and 6 week data imply that DNA damage in the lung is cumulative. Reducing exposure time, plus analyzing separate lung lobes for DNA damage or histopathology, supports a strategy to reduce and refine animal use in tobacco product testing and is aligned to the 3Rs (replacement, reduction and refinement).
Collapse
Affiliation(s)
| | - Patricia Ordoñez
- Vivotecnia Research S.L., Parque Científico de Madrid,
Tres Cantos,
Madrid,
Spain
| | - David Thorne
- British American Tobacco, R&D,
Southampton,
Hampshire,
UK
| | - David Walker
- British American Tobacco, R&D,
Southampton,
Hampshire,
UK
| | | | | | - Debbie Dillon
- British American Tobacco, R&D,
Southampton,
Hampshire,
UK
| | - Clive Meredith
- British American Tobacco, R&D,
Southampton,
Hampshire,
UK
| |
Collapse
|
9
|
Roemer E, Dempsey R, Lawless-Pyne J, Lukman S, Evans AD, Trelles-Sticken E, Wittke S, Schorp M. Toxicological assessment of kretek cigarettes part 4: Mechanistic investigations, smoke chemistry and in vitro toxicity. Regul Toxicol Pharmacol 2014; 70 Suppl 1:S41-53. [DOI: 10.1016/j.yrtph.2014.09.012] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2014] [Accepted: 09/29/2014] [Indexed: 10/24/2022]
|
10
|
Toxicological assessment of kretek cigarettes part 5: Mechanistic investigations, inhalation toxicity. Regul Toxicol Pharmacol 2014; 70 Suppl 1:S54-65. [DOI: 10.1016/j.yrtph.2014.09.015] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2014] [Accepted: 09/29/2014] [Indexed: 01/18/2023]
|
11
|
Roemer E, Dempsey R, Hirter J, Deger Evans A, Weber S, Ode A, Wittke S, Schorp M. Toxicological assessment of kretek cigarettes Part 6: The impact of ingredients added to kretek cigarettes on smoke chemistry and in vitro toxicity. Regul Toxicol Pharmacol 2014; 70 Suppl 1:S66-80. [DOI: 10.1016/j.yrtph.2014.11.016] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2014] [Revised: 11/28/2014] [Accepted: 11/29/2014] [Indexed: 10/24/2022]
|
12
|
Toxicological assessment of kretek cigarettes. Regul Toxicol Pharmacol 2014; 70 Suppl 1:S2-14. [DOI: 10.1016/j.yrtph.2014.11.015] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2014] [Revised: 11/27/2014] [Accepted: 11/29/2014] [Indexed: 11/23/2022]
|